Positive Phase 1/2 Results of AKCEA-APOCIII-LRx Presented at American College of Cardiology Annual Scientific Session & Expo

Akcea Therapeutics (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals (NASDAQ:IONS) today announced the presentation of a poster summarizing results from the completed Phase 1/2 clinical study of AKCEA-APOCIII-L_Rx at the American College of Cardiology (ACC) Annual Scientific Session & Expo on March 10, 2018, in Orlando, Florida.

As quoted in the press release:

“We are pleased to share the outcomes of this AKCEA-APOCIII-L_Rx study with the ACC community. The data showing significant and sustained reductions of multiple parameters, including ApoC-III and triglyceride levels, underscore the important regulatory role ApoC-III protein plays in controlling lipid levels in blood, and the potentially broad implications that reducing ApoC-III levels could have for cardiovascular health. We look forward to seeing the results from our AKCEA-APOCIII-L_Rx Phase 2 study in 2019,” said Dr. Louis O’Dea, chief medical officer at Akcea Therapeutics.

Click here to read the full press release.